Generic drug impact stacked growth narrative questioned Goldman Sachs downgrades pharmaceutical giant Novartis (NVS.US) rating to "sell"

According to the financial news app, Wall Street financial giant Goldman Sachs has downgraded Swiss pharmaceutical giant Novartis' stock rating from "neutral" to "sell" in its latest research report. At the same time, the target stock price has been slightly lowered from 95.00 Swiss francs to 94.00 Swiss francs, meaning that Goldman Sachs believes the stock will trend towards a weak trajectory in the next 12 months. Novartis is currently trading around 101 Swiss francs in the European stock market, while Novartis (NVS.US) in the US stock market's ADR trading price is reported at 127.70 US dollars, with a year-to-date return rate of 36%, outperforming the S&P 500 index significantly.